Effectiveness of laparoscopic sleeve gastrectomy in treating obesity and the co-morbidities

doi:10.3877/cma.j.issn.1674-0793.2020.04.005

Abstract

Abstract:

Objective

To analyze the effectiveness and safety of laparoscopic sleeve gastrectomy (LSG) in treating obesity and its co-morbidities.

Methods

The clinical data of fifty-eight patients with obesity who underwent LSG in Guizhou Provincial People’s Hospital from January 2016 to December 2018 were retrospectively analyzed. The effect of weight loss, the improvement of combined diseases and postoperative complications were observed.

Results

All operations were successfully completed in LSG. The mean %EWL at 3, 6 and 12 months after surgery were (65.4±12.3)%, (71.2%±15.2)% and (74.7±16.7)% respectively. The combined diseases were fatty liver, liver dysfunction, dyslipidemia, obstructive sleep apnea, hypertension, type 2 diabetes mellitus and hyperuricemia, which were significantly improved by 74.3%, 78.3%, 70.0%, 56.3%, 85.7%, 100.0% and 80.0% one year after surgery. Early complications occurred in 3.4% (2/58) of patients, and the common late complications were gastroesophageal reflux disease, cholecystolithiasis and acute pancreatitis.

Conclusion

LSG is effective and safe in treating obesity and its co-morbidities.

Key words: Gastrectomy, Obesity, Percentage of excess weight loss, Combined diseases, Complication

Shaoyong Wang, Qinyu Li, Zhongmin Zhang, Guanghui Wang. Effectiveness of laparoscopic sleeve gastrectomy in treating obesity and the co-morbidities[J]. Chinese Archives of General Surgery(Electronic Edition), 2020, 14(04): 257-260.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhptwkxwx.cma-cmc.com.cn/EN/10.3877/cma.j.issn.1674-0793.2020.04.005

https://zhptwkxwx.cma-cmc.com.cn/EN/Y2020/V14/I04/257

Figures/Tables 2

References 19

[1]	中国医师协会外科医师分会肥胖和糖尿病外科医师委员会. 中国肥胖和2型糖尿病外科治疗指南(2014) [J]. 糖尿病临床, 2014, 8(11): 499-504.
[2]	Vranešić Bender D, Krznarić Z. Nutritional and behavioral modification therapies of obesity: facts and fiction[J]. Dig Dis, 2012, 30(2): 163-167.
[3]	Rebibo L, Maréchal V, De Lameth I, et al. Compliance with a multidisciplinary team meeting’s decision prior to bariatric surgery protects against major postoperative complications[J]. Surg Obes Relat Dis, 2017, 13(9): 1537-1543.
[4]	Schauer PR, Bhatt DL, Kashyap SR. Bariatric surgery or intensive medical therapy for diabetes after 5 years[J]. N Engl J Med, 2017, 376(20): 1997.
[5]	Helmiö M, Victorzon M, Ovaska J, et al. Comparison of short-term outcome of laparoscopic sleeve gastrectomy and gastric bypass in the treatment of morbid obesity: A prospective randomized controlled multicenter SLEEVEPASS study with 6-month follow-up[J]. Scand J Surg, 2014, 103(3): 175-181.
[6]	Snehalatha C, Viswanathan V, Ramachandran A. Cutoff values for normal anthropometric variables in asian Indian adults[J]. Diabetes Care, 2003, 26(5): 1380-1384.
[7]	Almogy G, Crookes PF, Anthone GJ. Longitudinal gastrectomy as a treatment for the high-risk super-obese patient[J]. Obes Surg, 2004, 14(4): 492-497.
[8]	Boza C, Daroch D, Barros D, et al. Long-term outcomes of laparoscopic sleeve gastrectomy as a primary bariatric procedure[J]. Surg Obes Relat Dis, 2014, 10(6): 1129-1133.
[9]	Deitel M, Gagner M, Erickson AL, et al. Third International Summit: current status of sleeve gastrectomy[J]. Surg Obes Relat Dis, 2011, 7(6): 749-759.
[10]	Rawlins L, Rawlins MP, Brown CC, et al. Sleeve gastrectomy: 5-year outcomes of a single institution[J]. Surg Obes Relat Dis, 2013, 9(1): 21-25.
[11]	Wang X, Chang XS, Gao L, et al. Effectiveness of laparoscopic sleeve gastrectomy for weight loss and obesity-associated co-morbidities: A 3-year outcome from Mainland Chinese patients[J]. Surg Obes Relat Dis, 2016, 12(7): 1305-1311.
[12]	Peterli R, Wölnerhanssen BK, Peters T, et al. Effect of laparoscopic sleeve gastrectomy vs laparoscopic Roux-en-Y gastric bypass on weight loss in patients with morbid obesity: the SM-BOSS randomized clinical trial[J]. JAMA, 2018, 319(3): 255-265.
[13]	Salminen P, Helmiö M, Ovaska J, et al. Effect of laparoscopic sleeve gastrectomy vs laparoscopic Roux-en-Y gastric bypass on weight loss at 5 years among patients with morbid obesity: the SLEEVEPASS randomized clinical trial[J]. JAMA, 2018, 319(3): 241-254.
[14]	Nath A, Leblanc KA, Hausmann MG, et al. Laparoscopic sleeve gastrectomy: our first 100 patients[J]. JSLS, 2010, 14(4): 502-508.
[15]	Pradarelli JC, Varban OA, Ghaferi AA, et al. Hospital variation in perioperative complications for laparoscopic sleeve gastrectomy in Michigan[J]. Surgery, 2016, 159(4): 1113-1120.
[16]	Nath A, Yewale S, Tran T, et al. Dysphagia after vertical sleevegastrectomy: evaluation of risk factors and assessment of endoscopic intervention[J]. World J Gastroenterol, 2016, 22(47): 10371-10379.
[17]	Abou Rached A, Basile M, El Masri H. Gastric leaks post sleeve gastrectomy: review of its prevention and management[J]. World J Gastroenterol, 2014, 20(38): 13904-13910.
[18]	Gehrer S, Kern B, Peters T, et al. Fewer nutrient deficiencies after laparoscopic sleeve gastrectomy (LSG) than after laparoscopic Roux-Y-gastric bypass (LRYGB)-a prospective study[J]. Obes Surg, 2010, 20(4): 447-453.
[19]	Durmush EK, Ermerak G, Durmush D. Short-term outcomes of sleeve gastrectomy for morbid obesity: does staple line reinforcement matter?[J]. Obes Surg, 2014, 24(7): 1109-1116.

时间	脂肪肝	肝功能异常	血脂异常	呼吸睡眠暂停综合征	高血压	2型糖尿病	高尿酸血症
术前	35(60.3)	23(39.7)	20(34.4)	16(27.6)	14(24.1)	11(19.0)	10(17.2)
术后12个月	9(32.8)	5(8.6)	6(10.3)	7(12.1)	2(3.4)	0(0)	2(3.4)
χ2值	24.752	15.253	9.716	4.393	10.440	12.152	5.949
P值	<0.001	<0.001	0.002	0.036	0.001	<0.001	0.015

时间	脂肪肝	肝功能异常	血脂异常	呼吸睡眠暂停综合征	高血压	2型糖尿病	高尿酸血症
术前	35(60.3)	23(39.7)	20(34.4)	16(27.6)	14(24.1)	11(19.0)	10(17.2)
术后12个月	9(32.8)	5(8.6)	6(10.3)	7(12.1)	2(3.4)	0(0)	2(3.4)
χ2值	24.752	15.253	9.716	4.393	10.440	12.152	5.949
P值	<0.001	<0.001	0.002	0.036	0.001	<0.001	0.015

Please choose a citation manager

Content to export